{"schema_version":"secwatch.filing_event.v1","accession":"0001551152-23-000004","form_type":"8-K","ticker":"ABBV","cik":"0001551152","company_name":"AbbVie Inc.","filed_at":"2023-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.534235+00:00","generated_at":"2026-06-20T18:46:58.315700+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"AbbVie expects Q4 2022 $243M acquired IPR&D charge, cutting adjusted EPS by $0.14","bullets":["Q4 2022 acquired IPR&D and milestones expense of $243M pre-tax; $0.14 hit to GAAP and adjusted EPS.","Q4 2022 adjusted EPS guidance revised to $3.51-$3.55 from prior $3.65-$3.69.","Full-year 2022 adjusted EPS guidance revised to $13.70-$13.74 from prior $13.84-$13.88.","Results are preliminary and subject to financial statement closing procedures.","AbbVie does not forecast acquired IPR&D expense due to transaction uncertainty."],"urls":{"canonical":"https://secwatch.observer/filing/0001551152-23-000004","json":"https://secwatch.observer/filing/0001551152-23-000004.json","markdown":"https://secwatch.observer/filing/0001551152-23-000004.md","text":"https://secwatch.observer/filing/0001551152-23-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1551152/000155115223000004/0001551152-23-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1551152/000155115223000004/abbv-20230106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T18:46:58.315700+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bed2e3967ddd18afbc92f2f4eba5a415275df85d","claim":"AbbVie Inc. reported the quarter ended December 31, 2022 results: EPS $3.51 - $3.55. Guidance reaffirmed.","evidence_excerpt":"AbbVie’s fourth quarter 2022 adjusted diluted earnings per share guidance range, including the impact of fourth quarter 2022 acquired IPR&D and milestones expense, is $3.51 - $3.55.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115223000004/0001551152-23-000004-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended December 31, 2022"},{"label":"EPS","value":"$3.51 - $3.55"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"fb9f20a4ef3e0e1aa6994f4ac907e2d19447e0a8","claim":"AbbVie Inc. reported the full-year ended December 31, 2022 results: EPS $13.70 - $13.74. Guidance reaffirmed.","evidence_excerpt":"AbbVie’s full-year 2022 adjusted diluted earnings per share guidance range, including the impact of fourth quarter 2022 acquired IPR&D and milestones expense, is $13.70 - $13.74.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115223000004/0001551152-23-000004-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full-year ended December 31, 2022"},{"label":"EPS","value":"$13.70 - $13.74"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}